Search results for "ORPHAN DRUG|Designated/Approved|Treatment of HER2 colorectal cancer" in comments (approximate match)
Showing 1 - 1 of 1 results
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
TUCATINIB (ONT-380 or ARRY-380) is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and licensed to Cascadian Therapeutics (previously named Oncothyreon) for development, manufacturing and commercialization. ...